<DOC>
	<DOC>NCT02318706</DOC>
	<brief_summary>Investigate the efficacy and safety of DS-5565 in subjects with Diabetic Peripheral Neuropathic Pain (DPNP) in comparison to placebo</brief_summary>
	<brief_title>DS-5565 Phase III Study for Diabetic Peripheral Neuropathic Pain</brief_title>
	<detailed_description>[Double Blind Phase] The primary objective is to compare change in the Average Daily Pain Score(ADPS) from baseline to Week 14 in Asian subjects with DPNP receiving DS-5565 versus placebo. [Open Extension Phase] The objective is to assess the long-term safety and efficacy of DS-5565 in subjects with DPNP.</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>Type 1 or type 2 diabetes mellitus at screening Painful distal symmetric polyneuropathy At screening, a pain scale of â‰¥ 40 mm HbA1c (National Glycohemoglobin Standardization Program) &gt; 10.0%</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diabetic Peripheral Neuropathic Pain</keyword>
</DOC>